A Phase 3 interventional study of botulinum toxin neuromodulator and Placebo in Glabellar Frown Lines (GL) and Lateral Canthal Lines (LCL), sponsored by Galderma R&D. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
Biological: botulinum toxin neuromodulator · Biological: Placebo
A buffered solution; Mode of administration: intramuscular injection
Biological: Placebo
QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
Biological: botulinum toxin neuromodulator · Biological: Placebo
QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
Biological: botulinum toxin neuromodulator
QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
Also known as: QM1114-DP
Placebo will be injected into either the LCL, GL, or both the LCL and GL
Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown
Investigator 4-point Photographic Scale of Glabellar Line Severity represents the severity of GL from none (grade 0), mild (grade 1), moderate (grade 2) to severe (grade 3). Each grade is depicted by an individual photograph and a descriptive text. The Investigators used the 4-point Photographic Scale for direct, live comparison with the subject's face at maximum frown. Subjects made their assessment of glabellar line severity independently of the Investigator's assessment. Subjects were asked to evaluate their GL at maximum frown by grading the GL severity from none (grade 0, smooth skin), mild (grade 1, fairly smooth skin), moderate (grade 2, frown lines) to severe (grade 3, deep frown lines).
Time frame: Month 1
Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile
Investigator 4-point Photographic Scale of Lateral Canthal Line represents LCL severities from none (grade 0), mild (grade 1), moderate (grade 2), to severe (grade 3). Each grade is also depicted by an individual photograph and descriptive text. The Investigators used the LCL-ILA for direct, live comparison with the subject's face for grading LCL severity. Left and right LCL were assessed at maximum smile. Subject 4-point Photographic Scale of Lateral Canthal Line Severity represents LCL severities from Level 0, Level 1, Level 2, to Level 3. Each grade is also depicted by an individual photograph and descriptive text. Subjects made their assessments independently of the Investigator's assessment. Subjects evaluated their LCL severity (left and right side separately) at maximum smile.
Time frame: Month 1
Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown
Time frame: Month 1
Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.
Time frame: Month 1
| Milestone | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL |
|---|---|---|---|---|
| Started | 126 | 59 | 113 | 115 |
| Completed | 121 | 52 | 106 | 107 |
| Not completed | 5 | 7 | 7 | 8 |
Investigator 4-point Photographic Scale of Glabellar Line Severity represents the severity of GL from none (grade 0), mild (grade 1), moderate (grade 2) to severe (grade 3). Each grade is depicted by an individual photograph and a descriptive text. The Investigators used the 4-point Photographic Scale for direct, live comparison with the subject's face at maximum frown. Subjects made their assessment of glabellar line severity independently of the Investigator's assessment. Subjects were asked to evaluate their GL at maximum frown by grading the GL severity from none (grade 0, smooth skin), mild (grade 1, fairly smooth skin), moderate (grade 2, frown lines) to severe (grade 3, deep frown lines).
| Participants | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL (GL Data) |
|---|---|---|---|
| Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown | 0 | 75 | 78 |
Investigator 4-point Photographic Scale of Lateral Canthal Line represents LCL severities from none (grade 0), mild (grade 1), moderate (grade 2), to severe (grade 3). Each grade is also depicted by an individual photograph and descriptive text. The Investigators used the LCL-ILA for direct, live comparison with the subject's face for grading LCL severity. Left and right LCL were assessed at maximum smile. Subject 4-point Photographic Scale of Lateral Canthal Line Severity represents LCL severities from Level 0, Level 1, Level 2, to Level 3. Each grade is also depicted by an individual photograph and descriptive text. Subjects made their assessments independently of the Investigator's assessment. Subjects evaluated their LCL severity (left and right side separately) at maximum smile.
| Participants | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | QM1114-DP in the LCL + GL (LCL Data) |
|---|---|---|---|
| Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile | 53 | 0 | 59 |
| Participants | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL |
|---|---|---|---|
| Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown | 1 | 97 | 102 |
| Participants | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | QM1114-DP in the LCL + GL (LCL Data) |
|---|---|---|---|
| Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile. | 89 | 10 | 89 |
Collected over 6 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QM1114-DP in the LCL + Placebo in the GL | 0/123 (0%) | 0/123 (0%) | 9/123 (7.3%) |
| Placebo in the LCL and GL | 0/58 (0%) | 1/58 (1.7%) | 6/58 (10.3%) |
| Placebo in the LCL + QM1114-DP in the GL | 0/116 (0%) | 1/116 (0.9%) | 18/116 (15.5%) |
| QM1114-DP in the LCL + GL | 0/115 (0%) | 1/115 (0.9%) | 9/115 (7.8%) |
| Event | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL |
|---|---|---|---|---|
| Hypertensive emergencyVascular disorders | 0/123 | 1/58 | 0/116 | 0/115 |
| Enterocutaneous fistulaGastrointestinal disorders | 0/123 | 0/58 | 0/116 | 1/115 |
| AppendicitisInfections and infestations | 0/123 | 0/58 | 1/116 | 0/115 |
| DehydrationMetabolism and nutrition disorders | 0/123 | 0/58 | 1/116 | 0/115 |
| Event | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL |
|---|---|---|---|---|
| COVID-19Infections and infestations | 4/123 | 4/58 | 6/116 | 3/115 |
| HeadacheNervous system disorders | 3/123 | 0/58 | 6/116 | 4/115 |
| Injection site painGeneral disorders | 1/123 | 2/58 | 0/116 | 0/115 |
| Eyelid ptosisEye disorders | 0/123 | 0/58 | 3/116 | 0/115 |
| Injection site bruisingGeneral disorders | 2/123 | 1/58 | 3/116 | 2/115 |
| Age, Continuous(years) | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL | Total |
|---|---|---|---|---|---|
| Mean | 50.3 ± 10.44 | 49.8 ± 50.0 | 50.4 ± 9.77 | 50.5 ± 10.63 | 50.3 ± 10.2 |
| Sex: Female, Male(Participants) | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL | Total |
|---|---|---|---|---|---|
| Female | 113 | 55 | 103 | 97 | 368 |
| Male | 13 | 3 | 10 | 18 | 44 |
| Race (NIH/OMB)(Participants) | QM1114-DP in the LCL + Placebo in the GL | Placebo in the LCL and GL | Placebo in the LCL + QM1114-DP in the GL | QM1114-DP in the LCL + GL | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 6 | 2 | 7 | 6 | 21 |
| White | 115 | 54 | 105 | 105 | 379 |
| More than one race | 1 | 0 | 0 | 2 | 3 |
| Unknown or Not Reported | 3 | 1 | 0 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in Oct 2020, 7 months.
Results were first posted in Sep 2023, 2 years 11 months after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A